An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma

NCT05980507 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Molecular development strategy adjustment

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: ICI201

Sponsor

The First Affiliated Hospital of Soochow University